Physician profile
Michael C Willoughby
NPI 1457589582
$9,861.11
in general payments reported to CMS, 2019-2025
10 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,161 · 2020: $89.13 · 2021: $31.23 · 2022: $170 · 2023: $3,987 · 2024: $264 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,804 · Food and Beverage: $1,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,804.10 |
| Food and Beverage | $1,605.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,867.57 | 2019-2025 | Aveir, Ensite |
| Medtronic, INC. | $3,018.49 | 2023 | Micra, Selectsecure |
| Boston Scientific Corporation | $1,368.46 | 2019-2025 | Watchman Access System, Farapulse |
| Novartis Pharmaceuticals Corporation | $223.02 | 2022-2024 | |
| Cardiva Medical, INC. | $143.37 | 2023 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Vvcs 6-12f |
| Medtronic Vascular, INC. | $106.03 | 2019-2020 | |
| Kestra Medical Technology Services, INC. | $64.68 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.22 | 2019-2024 | Lifevest |
| Lundbeck LLC | $21.95 | 2019 | |
| Amgen INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Willoughby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.